The groundbreaking rise of Viagra has consistently remained a benchmark of pharmaceutical success, however its position within the broader sector now presents questions about long-term returns . Generic versions are undercutting exclusivity , prompting concerns that betting on companies closely tied to Viagra's former influence could be a problemat